Close Menu

Lung Cancer

News and reporting on lung cancer.

The device, named the Verisante Aura, uses Raman spectroscopy to measure levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions. In initial clinical trials it distinguished between benign and malignant lesions with 100-percent sensitivity and 70-percent specificity.

Precision Therapeutics has gained exclusive rights to the LungExpress Dx test.

Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.

According to the company's earnings statement, MDxHealth's product and service revenues nearly doubled – from €1 million in 2009 to €2 million in 2010 – due to several companion diagnostics deals and biomarker licensing agreements inked with major drug companies.

New Releases: Feb 23, 2011

Premium

Sigma Life Science's new cancer cell lines

Signal has alleged that Med BioGene breached the provisions in a term sheet inked between the two companies regarding an exclusive, worldwide license for Med BioGene's LungExpress Dx test.

The device, which the scientists are developing under a two-year, €1.3 million grant from Germany's Federal Ministry of Education and Research, uses cytometric bead arrays to quantitate protein biomarkers in patients' exhaled breath condensate.

The diagnostic is being developed using a new peptoid-based technique for detecting disease-specific antibodies that could prove broadly useful as a protein biomarker discovery tool, said a researcher.

BU will use grants from NCI and DOD with partners at UCLA, Vanderbilt, and MD Anderson to develop early-stage lung cancer diagnostics.

The test is intended both for early screening purposes and the differential diagnoses of lung nodules detected during CT scans and x-rays. SomaLogic has partnered with Quest Diagnostics to commercialize the test, with a lab-developed version slated for launch next year.

Pages

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.